At Sokolove Law, we're proud to announce we were awarded a $40.1 Million verdict for a U.S. Navy veteran client with ...
NovoCure Ltd. (($NVCR)) announced an update on their ongoing clinical study. In a recent update, NovoCure Ltd. announced the ongoing TIGER Meso ...
Providing expert legal guidance and emotional support, Toms River mesothelioma attorneys empower victims to navigate complex ...
Everyday Health on MSN
Coping With Body Image and Self-Esteem Issues After Endometrial Cancer Treatment
Endometrial cancer treatment and body image challenges often go hand in hand. Here’s how to cope and rebuild confidence after treatment.
From blood tests that predict recurrence to smarter, less invasive treatments, 2025 is delivering real hope—especially for ...
In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.
The phase 3 DREAM3R study randomized patients 2:1 to receive durvalumab 1500 mg every 3 weeks plus chemotherapy every 3 weeks for 4 to 6 cycles, followed by durvalumab maintenance 1500 mg every 4 ...
Latest Data from Phase I/II Study Reported in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and Published ...
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor ...
Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback